Article Information
History
- July 13, 2023.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Jason Bowera,
- Lester Chineryb,
- Alessandra Fleurentb,*,
- A. Metin Gülmezoglub,
- Wallada Im-Amornphongb,
- Catherine Kilfedderc,
- Petra Procterb and
- Alessandra Tomazzinib
- aIndependent consultant, London, UK
- bConcept Foundation, Geneva, Switzerland
- cInternational Planned Parenthood Federation, London, UK
- ↵*Corresponding author: Alessandra Fleurent (Avenue de Sécheron 15, 1202 Geneva, Switzerland, a.fleurent{at}conceptfoundation.org) Synopsis: Over half of mifepristone, misoprostol, and combipack samples collected and tested did not meet one or more requirements. One product was falsified.
Posted July 13, 2023.
